Thymia Ltd.

Thymia Ltd. develops a voice biomarker platform that analyses short samples of natural speech to infer health and safety states. The company describes its product as an infrastructure or "intelligence layer" for voice systems that operates separately from transcription and sentiment analysis, extracting biological signals from the acoustic properties of sound. According to its website, the platform derives more than 30 clinical and wellbeing states from roughly 15 seconds of speech in real time, spanning mental health (depression, anxiety, fatigue, stress), respiratory health (allergies, COVID-19, COPD, asthma), cardiovascular health (hypertension) and metabolic health (type 2 diabetes).

The company positions the technology as embeddable across any environment where voice is present, including telehealth, AI voice agents and assistants, contact centres, vehicles, video platforms, LLM providers, smart devices, telecommunications infrastructure and emergency lines. Thymia states that its technology is a registered medical device and that it is used by healthcare systems, automotive OEMs and North American first responder agencies. Its website reports headline accuracy figures of 86% for depression, 72% for fatigue and 61% for burnout, and cites 85%+ accuracy against gold standards across its models more broadly.

Thymia is registered in the United Kingdom (company number 12609104, VAT GB360012259) with an address at 9th Floor, 107 Cheapside, London EC2V 6DN. The site notes six years of R&D and clinical validation, a team of neuroscientists, physicists and machine learning engineers, and publishes technical documentation, an ethics and anonymity statement and a trust centre.

Business model

Thymia sells its voice biomarker capability as an infrastructure layer that other organisations embed into their own voice-based products and workflows, rather than as a standalone consumer application. Its website frames "every company using voice" — voice agents, contact centres, video platforms, LLM providers and telecoms infrastructure — as a potential partner, and it names healthcare systems, automotive OEMs and first responder agencies as users. Pricing and contract terms are not disclosed in the available sources.

Traction

Publicly stated traction consists of registered medical device status for its technology, named partnerships with Agora and Speechmatics, and claimed adoption by healthcare systems, automotive OEMs and North American first responder agencies. Research output is cited as 290+ publications, 12,000+ citations, a Nature journal family paper dated 2026, patents and unspecified awards. No customer counts, revenue or user metrics are disclosed in the sources.

Latest developments

Recent announcements listed on the company website include registration of its technology as a medical device, a partnership with Agora to enable health and safety signals across voice communications, and a collaboration with Speechmatics. Research posts cover symptom-level prediction of depression and anxiety from multimodal voice, personalised voice fatigue models that avoid constant AI retraining, and preliminary evidence that AI mental health screening transfers across cultures.